Ariadne (psychedelic)
From Wikipedia, the free encyclopedia
| Ariadne (psychedelic) | |
|---|---|
.png/200px-Ariadne_(psychedelic).png) |
|
 |
|
| IUPAC name | 1-(2,5-Dimethoxy-4-methyl-benzyl)-propylamine |
| Other names | 4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine 2-(4-Methyl-2,5-dimethoxyphenyl)ethan-alpha-ethylamine |
| Identifiers | |
| CAS number | |
| SMILES | COc1cc(C)c(cc1CC(C)N)OC |
| Properties | |
| Molar mass | 223.311 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Ariadne (α-Et-DOM), or 4-methyl-2,5-dimethoxy-alpha-ethylphenethylamine, is a lesser-known psychedelic drug. It is an analog of 2C-D and DOM. Ariadne was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin reported testing Ariadne up to a dose of 32 mg, and reported that it produces psychedelia and a bare threshold.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of Ariadne in humans apart from Shulgin's limited testing.
However, in more recent animal studies, α-Et-DOM was shown to produce stimulus generalisation in rats trained to respond to the drug MDMA.[2] This suggests that while α-Et-DOM may lack hallucinogenic effects, it might potentially produce empathogenic effects similar to those of MDMA if used at higher dose ranges, beyond those trialled by Shulgin (the potency of α-Et-DOM in this study was similar to that of MDMA, 1.5 mg/kg, which would equate to a dose of ~100 mg in a human).
[edit] References
- ^ Shulgin, Alexander; Ann Shulgin (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
- ^ Glennon RA. MDMA-Like Stimulus Effects of α-Ethyltryptamine and the α-Ethyl Homolog of DOM. Pharmacology, Biochemistry and Behaviour. 1993; 46: 459-462.
[edit] See also
[edit] External links
 |
This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
